GA-INSPIRE-BRANDS
17.1.2024 14:01:31 CET | Business Wire | Press release
Today, Inspire Brands announced two international franchise agreements to bring Jimmy John’s, the largest owned-delivery sandwich brand in the United States, to Canada and Latin America, launching the brand’s global expansion plan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240117651076/en/
Jimmy John's international store concept design (Photo: Business Wire)
Jimmy John's focus on quality ingredients, convenience and digital innovation blended with ease of operations uniquely positions the brand for international appeal. Its global expansion will usher in a new way for international guests to enjoy its iconic menu—the ability to order hot, toasted sandwiches as a customization option.
"For 40 years, Jimmy John's has taken a straightforward approach to making ridiculously good, quality sandwiches and it's now time to share them with the world," said Michael Haley, President & Managing Director, International for Inspire Brands. “In a global restaurant environment where simplicity is paramount, we're confident this brand is primed for extensive international growth."
Jimmy John’s has reached agreements with two strong operators who both possess significant quick service restaurant experience and have established extensive footprints throughout Canada and Latin America.
- Foodtastic - A leading franchisor of restaurant brands in Canada, with more than 1,100 restaurants and $1.1 billion in sales.
- Franquicias Internacionales - Based in El Salvador, has a robust portfolio of several complementary businesses across food and beverage, digital media and logistics.
Jimmy John’s obsessive approach to culinary excellence and operational efficiency has helped fuel its growth in the U.S. and will be the foundation of the brand’s international expansion.
Quality Obsessed:
- Bread baked fresh in the restaurant throughout the day
- Premium meats and cheeses, as well as fresh vegetables that are hand-sliced in restaurants daily
Convenience Obsessed:
- Sandwiches, customized to your liking, made fresh and fast right when you want them
- Speedy accessibility via drive-thru, pick-up, and delivery
Technology Obsessed:
- Industry-leading mobile app and online ordering enabled through POS integration
- Exclusive rewards through the international loyalty program
While Jimmy John's is just embarking on its global journey, Inspire Brands is no stranger to international expansion. As a multi-brand restaurant company with more than 32,000 locations worldwide, including Arby's®, Baskin-Robbins®, Buffalo Wild Wings®, Dunkin'®, Jimmy John's® and SONIC®, Inspire has a robust international presence, with more than 9,900 locations.
Jimmy John's global expansion will be supported by Inspire's extensible, shared services platform and its international team, which has a wealth of experience managing and operating brands globally.
To learn more about growth opportunities with Jimmy John’s and Inspire, please visit inspirebrands.com/franchising/international/.
About Inspire Brands
Inspire Brands is a multi-brand restaurant company whose portfolio includes more than 32,000 Arby’s, Baskin-Robbins, Buffalo Wild Wings, Dunkin’, Jimmy John’s, and SONIC locations worldwide. The company was founded in 2018 and is headquartered in Atlanta, Georgia. For more information, visit InspireBrands.com.
About Jimmy John’s
Jimmy John’s, founded in 1983, is the largest owned delivery sandwich brand in the United States, with more than 2,600 restaurants in 48 states. Jimmy John’s is part of the Inspire Brands family of restaurants. For more information, visit JimmyJohns.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240117651076/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
